Drug
Nezulcitinib clinical trials
Also written TD-0903.
- studies test it
- 3
- open now
- 0
- in phase 3
- 0
- first study started
- 2020
How studies write it
Studies that test it under each name
Development codes
- TD-0903
- 2
Studies by the year they started
3 studies that test it; most in 2020 (2)
| Year | Studies |
|---|---|
| 2020 | 2 |
| 2021 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 3 · Other 0
Related medicines
As reviewed, each with the page that says it.
- One of Janus Kinase Inhibitors source
- One of Protein Kinase Inhibitors source
- One of Tyrosine Kinase Inhibitors source
Studies
Open first, then newest update. How each study uses nezulcitinib is read from its arms, and is right about nine times in ten.
Testing it · 3
- TD-0903 for ALI Associated With COVID-19CompletedPhase 2Theravance BiopharmaNCT04402866Written as TD-0903
- TD-0903 Pharmacokinetics Study in Healthy Participants With Supplemental OxygenationCompletedPhase 1Theravance BiopharmaNCT05091723Written as Nezulcitinib (TD-0903) Dose A
- First in Human SAD and MAD Study of Inhaled TD-0903, a Potential Treatment for ALI Associated With COVID-19CompletedPhase 1Theravance BiopharmaNCT04350736Written as TD-0903
Codes
What other systems call nezulcitinib · ClinicalTrials.gg INT001723
- MeSH (NLM) C000719753nezulcitinibOne source NLM
- UNII (FDA) CXA4I8AH6ANEZULCITINIBConfirmed FDA, NLM
- NCI Thesaurus C177760NezulcitinibOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000719753 | nezulcitinib | One source NLM |
| UNII (FDA) | CXA4I8AH6A | NEZULCITINIB | Confirmed FDA, NLM |
| NCI Thesaurus | C177760 | Nezulcitinib | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.